Form 4: TG Therapeutics Director Laurence Charney Receives Restricted Stock Grant

TG Therapeutics, Inc. Director Laurence N. Charney was granted 21,408 shares of restricted common stock, increasing his total beneficial ownership to 222,887 shares.

Summary

• Laurence N. Charney, a Director of TG Therapeutics, Inc. (TGTX), acquired 21,408 shares of common stock.
• The acquisition was a grant of restricted shares with a transaction price of $0 per share.
• These newly granted restricted shares are scheduled to vest on June 12, 2026.
• Following this transaction, Mr. Charney's total beneficial ownership in TG Therapeutics, Inc. stands at 222,887 shares of common stock.
• The reported beneficial ownership includes shares of restricted Common Stock that vest over various time periods.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it indicates a director's increased stake and alignment of interests, but it's a routine compensation event rather than a significant strategic or financial announcement.

Positives

• The grant of restricted shares to a director, Laurence N. Charney, aligns his interests with those of the shareholders, potentially incentivizing long-term performance.
• The increase in a director's beneficial ownership demonstrates continued commitment to the company.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction; it solely reports an insider transaction.

Industry Context

This filing is a routine insider transaction report and does not provide information to analyze broader industry trends or competitive positioning within the biotechnology or pharmaceutical sector.

Related Party Transactions

• The transaction involves a grant of restricted shares from TG Therapeutics, Inc. to Laurence N. Charney, a Director of the company, which is a related party transaction in the context of executive compensation.

Stakeholder Impact

• Shareholders: The grant of restricted stock to a director can be seen as a positive for shareholders as it aligns the director's financial interests with the long-term performance of the company's stock.

Next Steps

• The 21,408 restricted shares granted to Laurence N. Charney are scheduled to vest on June 12, 2026.

Key Dates

Keywords

TG Therapeutics, TGTX, Laurence N. Charney, Director, Restricted Stock Grant, Insider Transaction, Beneficial Ownership, SEC Form 4, Equity Compensation